Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MK-7602,Artemether,Lumefantrine,Primaquine Diphosphate,Artesunate,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : MK-7602,Artemether,Lumefantrine,Primaquine Diphosphate,Artesunate,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Proguanil,Sulfasalazine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cambridge Study Spots Antimalarial, Arthritis Drugs for COVID
Details : Antimalarial therapy proguanil and rheumatoid arthritis medication sulfasalazine, showed they could safety inhibit the replication of the SARS-CoV-2 coronavirus behind COVID-19 in both monkey and human cell lines, according to a new study published in Sc...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Proguanil,Sulfasalazine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2019
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil,P. Falciparum Sporozoites
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Sanaria
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2016
Lead Product(s) : Atovaquone,Proguanil,P. Falciparum Sporozoites
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Sanaria
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2013
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2011
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mefloquine,Immunization,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2011
Lead Product(s) : Mefloquine,Immunization,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable